256 related articles for article (PubMed ID: 33376237)
21. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.
Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G
Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931
[TBL] [Abstract][Full Text] [Related]
22. [Effectiveness of P-Gemox chemotherapy combined with radiotherapy in newly diagnosed,stage ⅠE to ⅡE, extranodal nasal type natural killer/T-cell lymphoma].
Ji J; Li L; She NN; Liu XH; Long Y; Zhang XB
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Feb; 33(2):132-137. PubMed ID: 30808138
[No Abstract] [Full Text] [Related]
23. [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer].
Shi YX; Xu RH; Jiang WQ; Zhang L; Lin TY; Li YH; Xia ZJ; Luo HY; Han B; Wang F; He YJ; Guan ZZ
Ai Zheng; 2007 Dec; 26(12):1381-4. PubMed ID: 18076807
[TBL] [Abstract][Full Text] [Related]
24. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma.
Xiong J; Cheng S; Gao X; Yu SH; Dai YT; Huang XY; Zhong HJ; Wang CF; Yi HM; Zhang H; Cao WG; Li R; Tang W; Zhao Y; Xu PP; Wang L; Zhao WL
Signal Transduct Target Ther; 2024 Mar; 9(1):62. PubMed ID: 38448403
[TBL] [Abstract][Full Text] [Related]
25. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.
Wang L; Wang WD; Xia ZJ; Zhang YJ; Xiang J; Lu Y
Med Oncol; 2014 Mar; 31(3):860. PubMed ID: 24481637
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
[TBL] [Abstract][Full Text] [Related]
27. Dynamic evaluation of the prognostic value of
Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
[TBL] [Abstract][Full Text] [Related]
28. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Li X; Cui Y; Sun Z; Zhang L; Li L; Wang X; Wu J; Fu X; Ma W; Zhang X; Chang Y; Nan F; Li W; Su L; Wang J; Xue H; Zhang M
Clin Cancer Res; 2016 Nov; 22(21):5223-5228. PubMed ID: 27060152
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and safety of PD-1 inhibitor combined with chemotherapy in the primary treatment of phase Ⅲ/Ⅳ extranodal nasal-type natural killer/T cell lymphoma].
Liu YB; Yuan XL; Ma RJ; Jiang L; Wang LF; Zhu ZM
Zhonghua Yi Xue Za Zhi; 2021 Apr; 101(16):1178-1181. PubMed ID: 33902250
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
Park I; Kim BS; Lim HY; Kim HJ; Lee HJ; Choi YJ; Park KH; Lee KH; Yoon S; Hong B; Hong JH; Ahn H; Lee JL
Eur J Cancer; 2020 Mar; 127():183-190. PubMed ID: 31668839
[TBL] [Abstract][Full Text] [Related]
31. S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine.
Zhou Z; Li Z; Sun Z; Zhang X; Lu L; Wang Y; Zhang M
Sci Rep; 2016 Mar; 6():23695. PubMed ID: 27021626
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
Li J; Merl M; Lee MX; Kaley K; Saif MW
Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
Zhu AX; Meyerhardt JA; Blaszkowsky LS; Kambadakone AR; Muzikansky A; Zheng H; Clark JW; Abrams TA; Chan JA; Enzinger PC; Bhargava P; Kwak EL; Allen JN; Jain SR; Stuart K; Horgan K; Sheehan S; Fuchs CS; Ryan DP; Sahani DV
Lancet Oncol; 2010 Jan; 11(1):48-54. PubMed ID: 19932054
[TBL] [Abstract][Full Text] [Related]
34. A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.
Balzarotti M; Magagnoli M; Canales MÁ; Corradini P; Grande C; Sancho JM; Zaja F; Quinson AM; Belsack V; Maier D; Carlo-Stella C
Invest New Drugs; 2021 Aug; 39(4):1028-1035. PubMed ID: 33523334
[TBL] [Abstract][Full Text] [Related]
35. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
Wang L; Wang ZH; Chen XQ; Li YJ; Wang KF; Xia YF; Xia ZJ
Cancer; 2013 Jan; 119(2):348-55. PubMed ID: 22811078
[TBL] [Abstract][Full Text] [Related]
36. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
[TBL] [Abstract][Full Text] [Related]
38. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.
Ding H; Chang J; Liu LG; Hu D; Zhang WH; Yan Y; Ma LY; Li ZC; Ma YJ; Hao SG; Tao R
Int J Hematol; 2015 Aug; 102(2):181-7. PubMed ID: 25997870
[TBL] [Abstract][Full Text] [Related]
39. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
Corazzelli G; Capobianco G; Arcamone M; Ballerini PF; Iannitto E; Russo F; Frigeri F; Becchimanzi C; Marcacci G; De Chiara A; Pinto A
Cancer Chemother Pharmacol; 2009 Oct; 64(5):907-16. PubMed ID: 19219604
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China.
Zhang Y; Zhang W; Li J; Duan M; Han B; Zhu T; Zhuang J; Cai H; Cao X; Chen M; Zhou D
Ann Hematol; 2019 Jan; 98(1):143-150. PubMed ID: 30209556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]